<DOC>
	<DOCNO>NCT00551759</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , fluorouracil , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . Giving docetaxel cetuximab surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give chemotherapy radiation therapy together cetuximab follow surgery , docetaxel cetuximab work treat patient esophageal cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Cetuximab Followed Surgery , Docetaxel , Cetuximab Treating Patients With Esophageal Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine pathologic complete response ( pCR ) rate neoadjuvant chemoradiotherapy OX/5-FU/radiotherapy ( RT ) plus cetuximab patient resectable adenocarcinoma esophagus . Secondary - To evaluate safety neoadjuvant chemoradiotherapy OX/5-FU/RT plus cetuximab patient resectable adenocarcinoma esophagus . - To evaluate safety tolerability adjuvant therapy comprise cetuximab docetaxel patient . - To carry exploratory study determine activity regimen correlate epidermal growth factor receptor ( EGFR ) -related genetic pathway activation marker circulate endothelial tumor cell . OUTLINE : This multicenter study . - Neoadjuvant chemoradiotherapy cetuximab : Patients receive oxaliplatin intravenously ( IV ) 2 hour day 1 , 15 , 29 , cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 5-FU IV continuously 24 hour day 1-35 . Patients also undergo radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . Patients proceed surgery . - Surgery : Patients undergo surgical resection within 4-8 week completion neoadjuvant chemoradiotherapy cetuximab . Patients R0 R1 resection proceed adjuvant therapy . Patients whose tumor completely resect metastatic disease discontinue protocol therapy receive therapy discretion treat physician . - Adjuvant therapy : Within 4-8 week surgery , patient receive docetaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 . Treatment repeat every 6 week 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3-5 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Newly diagnose adenocarcinoma esophagus ( &gt; 20 cm incisor ) gastroesophageal ( GE ) junction , untreated chemotherapy , radiation therapy , surgery . Endoscopy biopsy dilation permit . Tumor stage T2N0M0 , T3N0M0 , T13N+M0 , T13N01M1A determine image study perform great 4 week prior registration , biopsy , appropriate . Celiac nodal metastasis ( M1A disease ) permit eligibility criterion meet . Data endoscopic ultrasound endoscopy require staging . The follow imaging require : CT scan IV contrast PET PET+CT . If PET/CT incorporate CT IV contrast , separate CT require . If laparoscopy relevant procedure perform , data incorporate stage assignment . Any lesion suspicious metastasis biopsied prove eligibility . Tumor extension cardia , present , must 2 cm . Tumors must consider surgically resectable ( T13 , T4 ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Granulocytes &gt; 1,000/ mm³ Platelets &gt; 100,000 μL Creatinine normal creatinine clearance &gt; 60 mL/min Total serum bilirubin &lt; 1.5 mg/dL Fertile patient must use effective contraception History curatively treat malignancy patient diseasefree ≥ 2 year survival prognosis &gt; 5 year Pregnant breastfeeding . Prior severe infusion reaction monoclonal antibody prior therapy specifically directly target epidermal growth factor receptor ( EGFR ) pathway Hypertension Uncontrolled diabetes Intercurrent illness would likely interfere protocol therapy prevent surgical resection Any follow within past 6 month : New York Heart Association class IIIIV congestive heart failure Cerebrovascular accident transient ischemic attack Unstable angina myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>cetuximab</keyword>
	<keyword>docetaxel</keyword>
</DOC>